RegCell

RegCell is a global biotechnology company pioneering cell therapies for autoimmune diseases and transplantation. Built on the groundbreaking discoveries of co-founder Professor Shimon Sakaguchi, a leader in regulatory T cell (T-reg) biology, RegCell’s newly established U.S. headquarters and its deep roots in Japan's renowned scientific community reinforce its innovative foundation. RegCell has developed a proprietary best-in-class platform for generating stable, epigenetically reprogrammed antigen-specific Tregs aimed at restoring immune tolerance. Current autoimmune treatments rely on immunosuppression, leading to ongoing adverse events and the need for lifelong therapy. RegCell’s platform overcomes key barriers hindering the development of autoimmune cell therapies by addressing unknown or multiple pathogenic antigens. Unlike gene-modification approaches, RegCell’s epigenetic reprogramming technology streamlines manufacturing, enhances safety, and enables scalable production, offering the promise of transformative cell therapies for a broad range of autoimmune patients, including those suffering from diseases driven by undefined autoantigens.